title: CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
abstract: BACKGROUND
  A 73-year-old Asian man with a history of lipidemia, hypertension and myocardial infarction presented with dizziness, decreased appetite, weight loss, nonproductive cough and fatigue. His physical performance status was good, and physical examination was unremarkable except for lower-extremity pitting edema.
  
  
  METHODS
  Physical examination, brain MRI, CT scans of the chest, abdomen and pelvis, bone scan, CT scan-guided biopsy, hematoxylin and eosin staining, EGFR mutational analysis, and chest X-ray.
  
  
  METHODS
  Stage IV non-small-cell lung cancer with brain metastasis.
  
  
  RESULTS
  Oral erlotinib 150 mg daily for 10 months and ongoing, and whole-brain irradiation.
authors: Division of Oncology and Hematology, Department of Pathology, Kaiser Permanente Medical Center, Santa Clara, CA, USA. mingui.pan@kp.org
authors: Minggui
authors: M
authors: Pan
authors: Monica
authors: M
authors: Santamaria
authors: David B
authors: DB
authors: Wollman
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology*; D008297:Male; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors